Search

Your search keyword '"Medeiros, L. Jeffrey"' showing total 4,891 results
Start Over Author "Medeiros, L. Jeffrey"
4,891 results on '"Medeiros, L. Jeffrey"'

102. Potential genetic mechanisms driving B/myeloid conversion in patients with follicular lymphoma and Langerhans cell neoplasms.

Author

Tashakori, Mehrnoosh and Medeiros, L. Jeffrey

Subjects
*LANGERHANS cells, *FOLLICULAR lymphoma, *GERMINAL centers, *TUMORS, *LYMPH nodes
Abstract

Transformation of follicular lymphoma (FL) to a Langerhans cell (LC) neoplasm is extremely uncommon. The shared IGH::BCL2 rearrangement is a robust finding in most transformed tumors underscoring that the cell of origin is perhaps a pre-B cell harboring IGH::BCL2 with the propensity to undergo further genetic alterations in the germinal centers of lymph nodes: does IGH::BCL2 in pre-B cells set off a plasticity cell state? Do FL and LC neoplasms develop separately through a common progenitor or via a multistep process of transdifferentiation or dedifferentiation/redifferentiation? Here, we review the literature and relevant cases presented in the Society for Hematopathology/European Association of Haematopathology 2021 Workshop to better understand this rare and complex phenomenon. We discuss clinical data, clonal relationship, and the mutational profile of these tumors and review proposed mechanisms of B/myeloid conversion based on in vitro and in vivo models. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

108. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

Author

Torka, Pallawi, Kothari, Shalin K., Sundaram, Suchitra, Li, Shaoying, Medeiros, L. Jeffrey, Ayers, Emily C., Landsburg, Daniel J., Bond, David A., Maddocks, Kami J., Giri, Anshu, Hess, Brian, Pham, Luu Q., Advani, Ranjana, Liu, Yang, Barta, Stefan Klaus, Vose, Julie M., Churnetski, Michael C., Cohen, Jonathon B., Burkart, Madelyn, Karmali, Reem, Zurko, Joanna, Mehta, Amitkumar, Olszewski, Adam J., Lee, Sarah, Hill, Brian T., Burns, Timothy F., Lansigan, Frederick, Rabinovich, Emma, Peace, David, Groman, Adrienne, Attwood, Kristopher, and Hernandez-Ilizaliturri, Francisco J.

Published
2020
Full Text
View/download PDF

113. T-Cell–Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features

Author

El Hussein, Siba, primary, Fang, Hong, additional, Jelloul, Fatima Zahra, additional, Wang, Wei, additional, Loghavi, Sanam, additional, Miranda, Roberto N., additional, Friedberg, Jonathan W., additional, Burack, W. Richard, additional, Evans, Andrew G., additional, Xu, Jie, additional, and Medeiros, L. Jeffrey, additional

Published
2023
Full Text
View/download PDF

114. Corrigendum to “Epstein–Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship.” [Modern Pathology 34 (2021) 2154–2167]

Author

Medeiros, L. Jeffrey, primary, Marques-Piubelli, Mario L., additional, Sangiorgio, Valentina F.I., additional, Ruiz-Cordero, Roberto, additional, Vega, Francisco, additional, Feldman, Andrew L., additional, Chapman, Jennifer R., additional, Clemens, Mark W., additional, Hunt, Kelly K., additional, Evans, Mark G., additional, Khoo, Christine, additional, Lade, Stephen, additional, Silberman, Mark, additional, Morkowski, Jerzy, additional, Pina, Edward M., additional, Mills, Daniel C., additional, Bates, Christopher M., additional, Magno, Winston B., additional, Sohani, Aliyah R., additional, Sieling, Beth A., additional, O’Donoghue, Joseph M., additional, Bacon, Chris M., additional, Patani, Neill, additional, Televantou, Despina, additional, Turner, Suzanne D., additional, Johnson, Laura, additional, MacNeill, Fiona, additional, Wotherspoon, Andrew C., additional, Iyer, Swaminathan P., additional, Malpica, Luis E., additional, Patel, Keyur P., additional, Xu, Jie, additional, and Miranda, Roberto N., additional

Published
2023
Full Text
View/download PDF

117. 86. Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation

Author

Nahmod, Karen, primary, Miranda, Roberto, additional, Vega, Francisco, additional, Thakral, Beenu, additional, Pemmaraju, Naveen, additional, Loghavi, Sanam, additional, Jelloul, Fatima, additional, Wang, Wei, additional, Wang, Sa, additional, Muzzafar, Tariq, additional, Patel, Keyur, additional, Bueso-Ramos, Carlos, additional, Medeiros, L. Jeffrey, additional, and Kanagal-Shamanna, Rashmi, additional

Published
2023
Full Text
View/download PDF

121. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes

Author

Lee, Hans C, Saliba, Rima M, Rondon, Gabriela, Chen, Julianne, Charafeddine, Yasmeen, Medeiros, L Jeffrey, Alatrash, Gheath, Andersson, Borje S, Popat, Uday, Kebriaei, Partow, Ciurea, Stefan, Oran, Betul, Shpall, Elizabeth, and Champlin, Richard

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Pediatric, Transplantation, Regenerative Medicine, Hematology, Cancer, Stem Cell Research, Pediatric Cancer, Rare Diseases, Clinical Research, Adult, Busulfan, Female, Graft Survival, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Myeloablative Agonists, Myelodysplastic Syndromes, Prognosis, Recurrence, Remission Induction, Retrospective Studies, Survival Analysis, T-Lymphocytes, Transplantation Chimera, Transplantation Conditioning, Transplantation, Homologous, Vidarabine, Acute myeloid leukemia, Chimerism, Myelodysplastic syndrome, Relapse, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Chimerism testing after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) represents a promising tool for predicting disease relapse, although its precise role in this setting remains unclear. We investigated the predictive value of T lymphocyte chimerism analysis at 90 to 120 days after allo-HSCT in 378 patients with AML/MDS who underwent busulfan/fludarabine-based myeloablative preparative regimens. Of 265 (70%) patients with available T lymphocyte chimerism data, 43% of patients in first or second complete remission (CR1/CR2) at the time of transplantation had complete (100%) donor T lymphocytes at day +90 to +120 compared with 60% of patients in the non-CR1/CR2 cohort (P = .005). In CR1/CR2 patients, donor T lymphocyte chimerism ≤ 85% at day +90 to +120 was associated with a higher frequency of 3-year disease progression (29%; 95% confidence interval [CI], 18% to 46% versus 15%; 95% CI, 9% to 23%; hazard ratio [HR], 2.1; P = .04). However, in the more advanced, non-CR1/CR2 cohort, mixed T lymphocyte chimerism was not associated with relapse (37%; 95% CI, 20% to 66% versus 34%; 95% CI, 25% to 47%; HR, 1.3; P = .60). These findings demonstrate that early T lymphocyte chimerism testing at day +90 to +120 is a useful approach for predicting AML/MDS disease recurrence in patients in CR1/CR2 at the time of transplantation.

Published
2015

127. List of Contributors

Author

Bell, Diana, primary, Bilodeau, Elizabeth Ann, additional, Bishop, Justin A., additional, Bouquot, Jerry Elmer, additional, Chernock, Rebecca, additional, Chi, Angela C., additional, Clark, Ashley, additional, Di Palma, Silvana, additional, Folpe, Andrew L., additional, Franchi, Alessandro, additional, Gale, Nina, additional, Gnepp, Douglas R., additional, Hall, Gillian, additional, Laver, Nora Marina V., additional, Lin, Pei, additional, Lingen, Mark William, additional, Medeiros, L. Jeffrey, additional, Mehrad, Mitra, additional, Montague, Lindsay, additional, Nadal, Alfons, additional, Nagao, Toshitaka, additional, Neville, Brad W., additional, Odell, Edward, additional, Richardson, Mary S., additional, Sandison, Ann, additional, Simpson, Roderick H.W., additional, Skalova, Alena, additional, Thavaraj, Selvam, additional, Wick, Mark Robert, additional, Williams, Michelle D., additional, Woo, Victoria L., additional, Wright, John, additional, and Zidar, Nina, additional

Published
2021
Full Text
View/download PDF

134. A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma

Author

Lyapichev, Kirill A., Piña-Oviedo, Sergio, Medeiros, L. Jeffrey, Evans, Mark G., Liu, Hui, Miranda, Alonso R., Hunt, Kelly K., Clemens, Mark W., Stewart, John M., Amin, Mitual B., Quesada, Andres E., Chai, Siaw Ming, Di Napoli, Arianna, Yoga, Arthy, Dave, Sanat K., Wistuba, Ignacio I., Wu, Yun, Bueso-Ramos, Carlos E., Schlette, Ellen J., Ferrufino-Schmidt, Maria C., Loghavi, Sanam, Khoury, Joseph D., Young, Ken H., and Miranda, Roberto N.

Published
2020
Full Text
View/download PDF

137. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma

Author

Ruiz-Cordero, Roberto, Rao, Priya, Li, Lerong, Qi, Yuan, Atherton, Daniel, Peng, Bo, Singh, Rajesh R., Kim, Tae-Beom, Kawakami, Fumi, Routbort, Mark J., Alouch, Nail, Chow, Chi-Wan B., Tang, Ximing, Lu, Wei, Brimo, Fadi, Matin, Surena F., Wood, Christopher G., Tannir, Nizar M., Wistuba, Ignacio I., Chen, Ken, Wang, Jing, Medeiros, L. Jeffrey, Karam, Jose A., Tamboli, Pheroze, and Sircar, Kanishka

Published
2019
Full Text
View/download PDF

148. Correction to: Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group

Author

Kanagal-Shamanna, Rashmi, Orazi, Attilio, Hasserjian, Robert P., Arber, Daniel A., Reichard, Kaaren, Hsi, Eric D., Bagg, Adam, Rogers, Heesun Joyce, Geyer, Julia, Darbaniyan, Faezeh, Do, Kim-Anh, Devins, Kyle M., Pozdnyakova, Olga, George, Tracy I., Cin, Paola Dal, Greipp, Patricia T., Routbort, Mark J., Patel, Keyur, Garcia-Manero, Guillermo, Verstovsek, Srdan, Medeiros, L. Jeffrey, Wang, Sa A., and Bueso-Ramos, Carlos

Published
2022
Full Text
View/download PDF

149. The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Author

Zhou, Yi, Slack, Rebecca, Jorgensen, Jeffrey L, Wang, Sa A, Rondon, Gabriela, de Lima, Marcos, Shpall, Elizabeth, Popat, Uday, Ciurea, Stefan, Alousi, Amin, Qazilbash, Muzaffar, Hosing, Chitra, O'Brien, Susan, Thomas, Deborah, Kantarjian, Hagop, Medeiros, L Jeffrey, Champlin, Richard E, and Kebriaei, Partow

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Regenerative Medicine, Pediatric, Transplantation, Rare Diseases, Hematology, Cancer, Stem Cell Research - Nonembryonic - Human, Clinical Research, Stem Cell Research, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Adolescent, Adult, Aged, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Neoplasm, Residual, Postoperative Period, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Preoperative Period, Prognosis, Recurrence, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Young Adult, Flow cytometry, Monitoring, Predictor, Relapse, Clinical Sciences, Oncology and Carcinogenesis, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

BackgroundAllogeneic HSCT is highly effective for treating ALL. However, many ALL patients relapse after HSCT. There has been a continuing effort to improve identification of patients at high risk of relapse, with the goal of early intervention to improve outcome.Patients and methodsIn this retrospective analysis, we examined the effect of MRD on the risk of hematologic relapse in 149 adult patients with ALL in morphologic remission undergoing allogeneic HSCT. MRD was assessed at the time of HSCT and after HSCT.ResultsPatients with pretransplant MRD had a trend for shorter progression-free survival (PFS) at 2 years compared with patients without MRD, nearing statistical significance; 28% versus 47%, P = .08, on univariate analysis. This trend remained on multivariate analysis with better PFS in patients without MRD at the time of HSCT, hazard ratio (HR), 0.62 (95% confidence interval, 0.37-1.04); P = .07. Additionally, emergence of MRD after HSCT was a strong predictor for overt hematologic relapse (HR, 4; P < .001) with a median latency interval of 3.8 months.ConclusionThese findings demonstrate the predictive value of monitoring for MRD around the time of transplant in adult patients with ALL.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results